• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

Skin disease linked to gadolinium prompts warning

Article

The risk that some patients have for developing a debilitating, life-threatening skin disease linked to the administration of gadolinium calls for close scrutiny of kidney function or even a higher threshold of glomular filtration rate.

The risk that some patients have for developing a debilitating, life-threatening skin disease linked to the administration of gadolinium calls for close scrutiny of kidney function or even a higher threshold of glomular filtration rate.

Around 400 cases of nephrogenic systemic fibrosis (NSF) have been idenitified worldwide, and most are related to the administration of gadodiamide (Omniscan, GE Healthcare) in patients with moderate to end-stage kidney disease, according to Prof. Henrik Thomsen, a radiologist at Copenhagen University Hospital in Denmark.

Patients with a GFR of < 30 mL/min and those on dialysis are at risk, Thomsen said. There also have been reports of patients with a serum creatinine below 2 mg/dL after gadodiamide administration, suggesting that the threshold could be set higher at < 60 mL/min.

GE Healthcare has posted warnings about gadodiamide on its website.

Related Videos
Improving the Quality of Breast MRI Acquisition and Processing
Can Fiber Optic RealShape (FORS) Technology Provide a Viable Alternative to X-Rays for Aortic Procedures?
Does Initial CCTA Provide the Best Assessment of Stable Chest Pain?
Making the Case for Intravascular Ultrasound Use in Peripheral Vascular Interventions
Can Diffusion Microstructural Imaging Provide Insights into Long Covid Beyond Conventional MRI?
Assessing the Impact of Radiology Workforce Shortages in Rural Communities
Emerging MRI and PET Research Reveals Link Between Visceral Abdominal Fat and Early Signs of Alzheimer’s Disease
Reimbursement Challenges in Radiology: An Interview with Richard Heller, MD
Nina Kottler, MD, MS
The Executive Order on AI: Promising Development for Radiology or ‘HIPAA for AI’?
Related Content
© 2024 MJH Life Sciences

All rights reserved.